Recombinant Human Cytochrome P450 7A1 (CYP7A1) Protein (His)

Name: Recombinant Human Cytochrome P450 7A1 (CYP7A1) Protein (His)
Brand: Beta LifeScience
SKU: BLC-07139P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: Other recombinant proteins, Recombinant proteins, Recombinant proteins fall special offers - full-length proteins, Recombinant proteins fall special offers - transmembrane proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Cytochrome P450 7A1 (CYP7A1) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P22680
Target Symbol	CYP7A1
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	MMTTSLIWGIAIAACCCLWLILGIRRRQTGEPPLENGLIPYLGCALQFGANPLEFLRANQRKHGHVFTCKLMGKYVHFITNPLSYHKVLCHGKYFDWKKFHFATSAKAFGHRSIDPMDGNTTENINDTFIKTLQGHALNSLTESMMENLQRIMRPPVSSNSKTAAWVTEGMYSFCYRVMFEAGYLTIFGRDLTRRDTQKAHILNNLDNFKQFDKVFPALVAGLPIHMFRTAHNAREKLAESLRHENLQKRESISELISLRMFLNDTLSTFDDLEKAKTHLVVLWASQANTIPATFWSLFQMIRNPEAMKAATEEVKRTLENAGQKVSLEGNPICLSQAELNDLPVLDSIIKESLRLSSASLNIRTAKEDFTLHLEDGSYNIRKDDIIALYPQLMHLDPEIYPDPLTFKYDRYLDENGKTKTTFYCNGLKLKYYYMPFGSGATICPGRLFAIHEIKQFLILMLSYFELELIEGQAKCPPLDQSRAGLGILPPLNDIEFKYKFKHL
Expression Range	1-504aa
Protein Length	Full Length
Mol. Weight	61.7 kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	A cytochrome P450 monooxygenase involved in the metabolism of endogenous cholesterol and its oxygenated derivatives (oxysterols). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Functions as a critical regulatory enzyme of bile acid biosynthesis and cholesterol homeostasis. Catalyzes the hydroxylation of carbon hydrogen bond at 7-alpha position of cholesterol, a rate-limiting step in cholesterol catabolism and bile acid biosynthesis. 7-alpha hydroxylates several oxysterols, including 4beta-hydroxycholesterol and 24-hydroxycholesterol. Catalyzes the oxidation of the 7,8 double bond of 7-dehydrocholesterol and lathosterol with direct and predominant formation of the 7-keto derivatives.
Subcellular Location	Endoplasmic reticulum membrane; Single-pass membrane protein. Microsome membrane; Single-pass membrane protein.
Protein Families	Cytochrome P450 family
Database References	HGNC: 2651 OMIM: 118455 KEGG: hsa:1581 STRING: 9606.ENSP00000301645 UniGene: Hs.1644
Tissue Specificity	Detected in liver.

Gene Functions References

miR-17 is a novel regulator of CYP7A1 signaling in hepatic lipid metabolism, by which miR-17 may mediate hepatosteatosis. PMID: 29721023
Rev-erbalpha regulates Cyp7a1 and cholesterol metabolism through its repression of the Lrh-1 receptor. PMID: 29237721
The analysis of the relationship of polymorphic variants CYP7A1 to lipid metabolic disturbances makes it possible to consider the AA homozygous genotype of variant mutation CYP7A1 rs 38088607 as protective against Dyslipidemia. PMID: 29171472
Genetic polymorphisms of CYP7A1 may be associated with susceptibility to anti-tuberculosis drug-induced hepatotoxicity in the Chinese population PMID: 27155186
The pronounced TC reduction in G allele carriers of rs3808607 observed in the previous study may be due to enhanced bile acid synthesis in response to high-viscosity beta-glucan consumption in those individuals. PMID: 29115200
Current studies suggest that increased Cyp7a1 expression and bile acid synthesis ameliorate hepatic inflammation through activation of FXR PMID: 27534992
This study provides evidence that individuals carrying the G allele of CYP7A1 single nucleotide polymorphism are more responsive to high molecular weight beta-glucan's effect of lowering circulating cholesterol concentrations than individuals homozygous for the T allele. PMID: 26936139
Genetic variations in ABCG5, CYP7A1, and DHCR7 may contribute to differing responses of serum cholesterol to dairy intake among healthy adults. PMID: 27052530
The promoter polymorphism of the CYP7A1 gene has a pronounced impact on diurnal variation in CYP7A1 activity. PMID: 27106353
The finding that overexpression of HIF-1alpha increased the activity of the CYP7A1 promoter suggested that hypoxia decreased the expression of CYP7A1 in a HIF-1-independent manner. PMID: 26521940
Macrophage cholesterol efflux in patients with type II diabetes mellitus was significantly reduced, and that this reduction was associated with the down-regulation of CYP7A1 expression. PMID: 26345803
CYP7A1 and APOE isoform are associated with the extent of reduction in circulating LDL cholesterol in response to plant sterols consumption. PMID: 26333513
The CYP7A1 rs7833904 polymorphism may modify the risk of CAD. PMID: 25944972
The CYP7A1 crystallographic models identify residues involved in cholest-4-en-3-one binding. PMID: 24927729
genetic polymorphism is associated with the total cholesterol level and the lipid-lowering efficacy of statin treatment. [meta-analysis] PMID: 25499945
we identified for the first time a significant association of the A-204C polymorphism of the CYP7A1 gene and development of tuberculosis in a Moroccan population PMID: 25360185
The CYP7A1 -204A>C polymorphism is significantly associated with serum lipid levels in Asian population, but not gallbladder stone disease. [Meta-analysis] PMID: 25103562
Cyp7a1 is a direct Thyroid hormone receptor (TR) target gene that responds to physiologic TR levels through a set of distinct response elements in its promoter. PMID: 24582860
Activation of the VDR represses hepatic SHP to increase levels of CYP7A1 and reduce cholesterol. PMID: 24365583
Two known single nucleotide polymorphisms were identified in the 5'-UTR of CYP7A1 and both were associated with neuromyelitis optica but not with Multiple sclerosis. PMID: 23740208
Genetic variants of CYP7A1 and its transcriptional activators (HNF4A and PPARGC1A) may activate bile acid synthesis, resulting in the accumulation of bile acids in hepatocytes leading primary biliary cirrhosis progression. PMID: 23354620
Prox1 interacts with LSD1 to recruit the repressive LSD1/NuRD complex to CYP7A1 promoter and co-represses transcription through epigenetic mechanisms. PMID: 23626788
A variant of COUP-TFII downregulates the function of COUP-TFII by inhibiting its binding to DNA, decreasing Cyp7a1 expression. PMID: 23458092
HNF4alpha and LRH-1 promote active transcription histone marks on the Cyp7a1 promoter that are reversed by FGF19 in a SHP-dependent manner PMID: 23038264
Liver X receptor alpha is required for induction of trascription of CYP7A1 in response to resveratrol. PMID: 22607622
these data suggest that FGF7 is a novel regulator of CYP7A1 expression in hepatocytes and may prevent hepatocytes from accumulating toxic bile acids during liver injury and fibrosis. PMID: 22713451
gender, but not SLCO1B1 or CYP7A1 polymorphism, has a major effect on the fasting plasma concentrations of individual bile acids PMID: 21902813
CYP7A1 polymorphisms are associated with colorectal adenoma. PMID: 22058145
The main enzyme regulating bile acids biosynthesis is CYP7A1 (7alpha-cholesterol hydroxylase). [review] PMID: 22235657
7-dehydrocholesterol (the immediate precursor of cholesterol) is oxidized by P450 7A1 to 7-ketocholesterol. PMID: 21813643
The frequencies of rs3808607 alleles in the CYP7A1 gene differed significantly between obese hypertensive and normotensive men. PMID: 21346769
Results suggest that promoter -204A > C variant is associated with enhanced CYP7A1 activity. PMID: 20884100
Cytochrome P450 7A1 cholesterol 7alpha-hydroxylation: individual reaction steps in the catalytic cycle and rate-limiting ferric iron reduction. PMID: 21147774
The mRNA expression levels of sodium taurocholate cotransporting polypeptide, bile salt export pump, and hepatic cholesterol 7alpha-hydroxylase were significantly higher in the primary biliary cirrhosis patients than in the controls. PMID: 20857261
These results demonstrate that no association exists between apoB-100, apoE, and CYP7A1 polymorphisms and cholelithiasis in a Mexican population. PMID: 20872969
study found glucose positively regulated hepatocyte CYP7A1 gene & bile acid synthesis; this glucose-mediated induction of CYP7A1 transcription may be mediated by both AMPK-dependent pathway & epigenetic regulation of CYP7A1 chromatin structure PMID: 19965590
miR-122a and miR-422a may destabilize CYP7A1 mRNA to inhibit CYP7A1 expression. PMID: 20351063
insulin is involved in the regulation of diurnal variation of CYP7A1 activity in humans PMID: 19537927
Statistical analyses revealed that a common promoter SNP in CYP7A1 has a protective/gene dose-dependent effect on the risk of NMO. PMID: 19850125
mechanism for gallbladder cancer susceptibility by CYP7A1 haplotype appears to be independent of gallstone pathway and is believed to involve genotoxicity resulting from subnormal bile acid production PMID: 20005541
The study provides evidence that -278A>C polymorphism in the CYP7A1 gene can modify triglyceride concentrations in response to a reduced fat diet in a dyslipidemic male population. PMID: 19448895
CYP7A1 regulates the pathway through which cholesterol is converted into bile acids. PMID: 11907135
regulation of CYP7A1 and CYP27A1 in human liver PMID: 12011083
Human CYP7A1 deficiency: progress and enigmas. Review. PMID: 12093884
New metabolic disorder presenting with hyperlipidemia caused by a homozygous deletion mutation in CYP7A1. PMID: 12093894
data suggest that the lack of an LXR element in the region from -56 to -49 of the human CYP7A1 promoter may account for some of the differences in response to diets between humans and rodents PMID: 12202481
characterization of the coordinated regulation of cholesterol metabolism in human liver; regulation of its mRNA in liver PMID: 12213890
Data reveal a fundamental difference in the regulation of CYP7A1 in rodent and human hepatocytes. PMID: 12554795
demonstrated that FGF-19, acting as an FXR-induced signaling molecule, represses expression of the CYP7A1 gene; this signaling cascade defines a novel mechanism for feedback repression of bile acid biosynthesis PMID: 12815072
bile acids suppress transcription of the gene (CYP7A1) encoding cholesterol 7alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis PMID: 12865425

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.